What is Acclinate?
Acclinate is a pioneering digital health company dedicated to enhancing the representation and diversity of participants in genomic research and clinical trials. Founded by Del Smith and Tiffany Jordan-Whitlow, the company empowers biopharmaceutical firms and contract research organizations (CROs) to engage diverse populations, thereby fostering more inclusive and representative health data. Acclinate's mission is to educate and enable individuals from diverse backgrounds to make informed decisions about their health and participation in research, addressing critical gaps in health equity within the life sciences sector.
How much funding has Acclinate raised?
Acclinate has raised a total of $10.5M across 2 funding rounds:
Series A
$7M
Debt
$3.5M
Series A (2024): $7M with participation from Labcorp
Debt (2026): $3.5M, investors not publicly disclosed
Key Investors in Acclinate
Labcorp
Labcorp is a global leader in life sciences, providing essential diagnostic, drug development, and technology-based services. Their involvement suggests a strategic alignment with Acclinate's mission to improve diversity in clinical trials and genomic research.
What's next for Acclinate?
With its recent major strategic investment and substantial enterprise-level backing, Acclinate is poised for accelerated expansion. The company's focus on bridging the gap in diversity for genomic research and clinical trials positions it at the forefront of a critical industry need. Future strategic initiatives are likely to involve scaling its engagement platforms, forging deeper partnerships with biopharmaceutical companies and CROs, and further developing its educational resources to drive broader participation. This capital infusion will be instrumental in solidifying Acclinate's market position and advancing its mission to create more equitable health outcomes through inclusive research.
See full Acclinate company page
